Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd plus low-dose apatinib for HR-positive HER2-low metastatic breast cancer
ChiCTR2400083481Phase 2Not yet recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Apr 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan and Rivoceranib in breast cancer, sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoint: objective response rate. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecanRivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400083481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083481.